Che‐Leung Law

6.5k citations

99 papers · 5.0k indexed · 1 hit paper · h-index 36

Immunology top 1%
Oncology top 1%
Molecular Biology top 5%
Radiology, Nuclear Medicine and Imaging top 0.5%
Pathology and Forensic Medicine top 2%

Co-authors: Edward A. Clark Sidorenko Sp Kristine A. Gordon Iqbal S. Grewal Peter D. Senter Alan F. Wahl Charles G. Cerveny Kerry Klussman
Topics: Monoclonal and Polyclonal Antibodies Research (58 papers)HER2/EGFR in Cancer Research (21 papers)T-cell and B-cell Immunology (20 papers)
Cited by: Immunology Immunology and Allergy Radiology, Nuclear Medicine and Imaging
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Che‐Leung Law

98 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

2003 668 citations Damon L. Meyer, Kerry Klussman et al. profile →

Peers

Countries citing papers authored by Che‐Leung Law

Since Specialization

Citations

This map shows the geographic impact of Che‐Leung Law's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Che‐Leung Law with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Che‐Leung Law more than expected).

Fields of papers citing papers by Che‐Leung Law

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Che‐Leung Law. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Che‐Leung Law. The network helps show where Che‐Leung Law may publish in the future.

Co-authorship network of co-authors of Che‐Leung Law

This figure shows the co-authorship network connecting the top 25 collaborators of Che‐Leung Law. A scholar is included among the top collaborators of Che‐Leung Law based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Che‐Leung Law. Che‐Leung Law is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Brentuximab Vedotin–Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity 2023 ·Molecular Cancer Therapeutics ·Ryan A. Heiser,Anthony Cao,Weiping Zeng,Michelle Ulrich,(unknown),Martha E. Anderson,Esther S. Trueblood,Mechthild Jonas,(unknown),Che‐Leung Law,Shyra J. Gardai	28
2	Preclinical Characterization of HPN536, a Trispecific, T-Cell–Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors 2020 ·Clinical Cancer Research ·(unknown),Richard J. Austin,Bryan D. Lemon,Wade H. Aaron,(unknown),(unknown),Susan Dana Jones,(unknown),(unknown),Kenneth G. Sexton,(unknown),Timothy Z. Yu,Patrick A. Baeuerle,Che‐Leung Law,Holger Wesche	35
3	Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates 2017 ·Molecular Cancer Therapeutics ·Fu Li,Michelle Ulrich,Mechthild Jonas,Ivan J. Stone,(unknown),Xinqun Zhang,Lori Westendorf,Dennis R. Benjamin,Che‐Leung Law	53
4	Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models 2016 ·Cancer Research ·Li Fu,Kim K. Emmerton,Mechthild Jonas,Xinqun Zhang,Jamie B. Miyamoto,Jocelyn R. Setter,Nicole D. Nicholas,Nicole M. Okeley,Robert P. Lyon,Dennis R. Benjamin,Che‐Leung Law	231
5	Lack of anti‐factor Xa assay standardization results in significant low molecular weight heparin (enoxaparin) dose variation in neonates and children 2014 ·Journal of Thrombosis and Haemostasis ·Lloyd A. Greene,Che‐Leung Law,(unknown),(unknown),Vera Ignjatović,Paul Monagle,Leslie Raffini	16
6	Distinct Apoptotic Signaling Characteristics of the Anti-CD40 Monoclonal Antibody Dacetuzumab and Rituximab Produce Enhanced Antitumor Activity in Non-Hodgkin Lymphoma 2011 ·Clinical Cancer Research ·Timothy S. Lewis,(unknown),Kim K. Emmerton,Jeffrey Lau,Shang‐Fan Yu,Julie A. McEarchern,Iqbal S. Grewal,Che‐Leung Law	27
7	5-Azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia 2010 ·mAbs ·May Kung Sutherland,Changpu Yu,Martha E. Anderson,Weiping Zeng,Nico van Rooijen,Eric L. Sievers,Iqbal S. Grewal,Che‐Leung Law	24
8	Blocking of CD27-CD70 Pathway by Anti-CD70 Antibody Ameliorates Joint Disease in Murine Collagen-Induced Arthritis 2009 ·The Journal of Immunology ·Ezogelin Oflazoglu,Tamar E. Boursalian,Weiping Zeng,Ana C. Edwards,(unknown),Julie A. McEarchern,Che‐Leung Law,Hans‐Peter Gerber,Iqbal S. Grewal	47
9	Targeting CD70 for Human Therapeutic Use 2009 ·Advances in experimental medicine and biology ·Tamar E. Boursalian,Julie A. McEarchern,Che‐Leung Law,Iqbal S. Grewal	36
10	Novel Antibody-Based Therapeutic Agents Targeting CD70: A Potential Approach for Treating Waldenström's Macroglobulinemia 2009 ·Clinical Lymphoma & Myeloma ·Che‐Leung Law,Julie A. McEarchern,Iqbal S. Grewal	4
11	Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia 2009 ·mAbs ·May Kung Sutherland,Changpu Yu,Timothy S. Lewis,Jamie B. Miyamoto,(unknown),Mechthild Jonas,Jennifer Sutherland,Albina Nesterova,Hans‐Peter Gerber,Eric L. Sievers,Iqbal S. Grewal,Che‐Leung Law	32
12	Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70 2008 ·Clinical Cancer Research ·Julie A. McEarchern,Leia M. Smith,Charlotte F. McDonagh,Kerry Klussman,Kristine A. Gordon,(unknown),Steven Duniho,Maureen C. Ryan,Tamar E. Boursalian,Paul J. Carter,Iqbal S. Grewal,Che‐Leung Law	70
13	Humanized anti-CD19 auristatin antibody-drug conjugates display potent antitumor activity in preclinical models of B-cell malignancies 2007 ·Molecular Cancer Therapeutics ·Hans‐Peter Gerber,(unknown),Ivan J. Stone,Mechthild Jonas,(unknown),Jamie B. Miyamoto,Lindsay L. Brown,Lori Westendorf,Damon L. Meyer,Django Sussman,Paul Carter,Che‐Leung Law,Iqbal S. Grewal	2
14	The humanized anti-CD40 monoclonal antibody, SGN-40, signals apoptosis in non-Hodgkin's lymphoma by dual mechanisms 2007 ·Molecular Cancer Therapeutics ·(unknown),Timothy S. Lewis,Jamie B. Miyamoto,May Kung Sutherland,Jonathan G. Drachman,Iqbal S. Grewal,Che‐Leung Law	1
15	Expression and characterization of recombinant soluble human CD3 molecules: presentation of antigenic epitopes defined on the native TCR–CD3 complex 2002 ·International Immunology ·Che‐Leung Law,Martha Hayden-Ledbetter,(unknown),(unknown),Hieu Nguyen,(unknown),Barbara A. Thorne,(unknown),Jeffrey A. Ledbetter	11
16	Tyrosine Phosphorylation of the Fc Receptor γ-Chain in Collagen-stimulated Platelets 1996 ·Journal of Biological Chemistry ·Jonathan M. Gibbins,Judith Asselin,Richard W. Farndale,Michael J. Barnes,Che‐Leung Law,Steve P. Watson	193
17	CD22 associates with protein tyrosine phosphatase 1C, Syk, and phospholipase C-gamma(1) upon B cell activation. 1996 ·The Journal of Experimental Medicine ·Che‐Leung Law,Sidorenko Sp,(unknown),Z Zhao,S H Shen,Edmond H. Fischer,Edward A. Clark	172
18	Protein Kinase C μ (PKCμ) Associates with the B Cell Antigen Receptor Complex and Regulates Lymphocyte Signaling 1996 ·Immunity ·Sidorenko Sp,Che‐Leung Law,Stephen J. Klaus,(unknown),Minoru Takata,Tomohiro Kurosaki,Edward A. Clark	115
19	Cell-cell interactions that regulate the development of B-lineage cells 1994 ·Current Opinion in Immunology ·Che‐Leung Law,Edward A. Clark	14
20	Differentiation of normal human pre-B cells in vitro. 1990 ·The Journal of Experimental Medicine ·Judith G. Villablanca,Janet Anderson,Melinda L. Moseley,Che‐Leung Law,Rebecca Elstrom,Tucker W. LeBien	38

About Che‐Leung Law

Che‐Leung Law is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Immunology and Allergy, having authored 99 papers that have together received 5.0k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (58 papers), HER2/EGFR in Cancer Research (21 papers) and T-cell and B-cell Immunology (20 papers). The work is most often cited by research in Immunology (2.3k citations), Immunology and Allergy (509 citations) and Radiology, Nuclear Medicine and Imaging (1.5k citations). Che‐Leung Law has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Edward A. Clark, Sidorenko Sp, Kristine A. Gordon, Iqbal S. Grewal, Peter D. Senter, Alan F. Wahl, Charles G. Cerveny, Kerry Klussman, Damon L. Meyer and Svetlana O. Doronina. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact